Brenig Therapeutics Advances Two CNS Programs Into Key Clinical Milestones

Brenig Therapeutics Advances Two CNS Programs Into Key Clinical Milestones

By, Admin 16 January 2026

Brenig Therapeutics, Inc., a clinical-stage biotech, has initiated its first-in-human study for BT-409, a brain-selective NLRP3 inflammasome inhibitor. The company also shared progress on BT-267, its CNS-optimized LRRK2 inhibitor for Parkinson’s disease.

BT-409 Enters First-in-Human Clinical Testing

BT-409 is a small-molecule, brain-selective NLRP3 inhibitor licensed from Mwyngil Therapeutics.

The compound was discovered and optimized using Brenig’s AI- and machine learning–enabled platform, with emphasis on:

  • Central nervous system penetration
  • High potency
  • Pharmacokinetics suitable for chronic neurological use

Phase 1 Study Design

Brenig has initiated a Phase 1 SAD/MAD study in healthy volunteers.

The trial will evaluate:

  • Safety and tolerability
  • Pharmacokinetics
  • Pharmacodynamic activity

First dosing is expected in early Q1 2026.

What Comes Next?

If Phase 1 is successful, Brenig plans proof-of-concept studies in:

  • Multiple sclerosis
  • Parkinson’s disease

The program targets neuroinflammation and neurodegeneration via central inflammasome inhibition.

BT-267 Continues Clinical Momentum in Parkinson’s Disease

BT-267 is a highly selective, brain-optimized LRRK2 inhibitor designed to maximize CNS exposure while limiting peripheral effects.

Early clinical data show:

  • Favorable pharmacokinetics
  • Sustained CNS exposure above predicted LRRK2 IC50 levels
  • Encouraging safety and tolerability

Upcoming Studies

Brenig plans to:

  • Initiate a Phase 1b study
  • Begin start-up activities for a Phase 2 proof-of-concept trial in Parkinson’s disease

Both are targeted for early 2026.

Strategic Focus: CNS-First Drug Design

Both BT-409 and BT-267 reflect Brenig’s strategy of precision CNS drug engineering.

Key design principles include:

  • High brain permeability
  • Strong target selectivity
  • Disease-modifying potential

The company is positioning both programs for efficient clinical translation.

About Brenig Therapeutics

Founded in 2021, Brenig Therapeutics focuses on small-molecule therapies for neurodegenerative diseases.

The company raised $65 million in Series A financing in July 2024, led by NEA, with participation from OrbiMed, Torrey Pines, and others. Brenig’s mission is clear: target core disease mechanisms and move faster from discovery to patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!